首页> 外文会议>Conference on Biomarkers in AKI (Acute Kidney Injury) >Pathogenesis of Cardiorenal Syndrome Type 1 in Acute Decompensated Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)
【24h】

Pathogenesis of Cardiorenal Syndrome Type 1 in Acute Decompensated Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)

机译:急性失代偿性心力衰竭中生心眼综合征1型的发病机制:急性透析质量倡议的第十一协商会大会(ADQI)的工作组陈述

获取原文

摘要

Pathophysiological mechanisms of cardiorenal syndromes (CRS) types 1 -5 are still sparsely characterized. In an attempt to address this issue, a consensus conference on CRS was held in Venice,italy, in November 2012 under the auspices of the Acute Dialysis Quality Initiative (ADQI). Working group 1 discussed monodirectional mechanisms of CRS type 1 which is characterized by a rapid worsening of cardiac function leading to acute kidney injury (AKI). Pre-conference we performed a systematic search and review of the available literature using a modified Delphi analysis. Hereby identified and in this review discussed questions were: (i) What are the predominant pathophysiologic mechanisms of CRS type 1 in acute decompensated heartfailure? (ii) Could biomarker profiling identify pathomech-anisms or hemodynamic phenotype of patients with CRS type 1? Could predictive bio-markers improve renal safety of therapy in CRS type 1? (iii) How do the timing, severity and duration relate to the mechanisms and outcomes of CRS type 1 ? In summary, after discussion and appraisal of the best available evidence, working group 1 makes consensus recommendations for future research on pathologic mechanisms of CRS type 1 and recommendations for clinical practice where treatment is in either proof or disproof of a mechanism.
机译:心肾综合症(CRS)类型1-5的病理生理机制仍然稀疏表征。在试图解决这个问题,在CRS共识会议在意大利威尼斯的急性透析质量倡议(ADQI)的主持下举行,2012年11月。工作组1所讨论的CRS类型1,它的特征是快速心功能恶化导致急性肾损伤(AKI)的单向机构。会前,我们采用改进德尔菲分析执行现有的文献进行了系统的搜索和审查。据此确定并在本次审查讨论的问题是:(1)什么是急性CRS型的主要病理生理机制失代偿性心力衰竭? (ⅱ)能生物标志物谱鉴定pathomech-anisms或患者的血液动力学CRS表型1型?可以预测的生物标志物改善CRS治疗肾安型1? (ⅲ)如何定时,严重程度和持续时间涉及CRS类型1的机制和结果?总之,讨论和现有的最佳证据的评估,工作组1个品牌协商一致的建议为今后CRS的病理机制研究后键入1和建议,供临床实践中这种药物是一种机制的任何证明或反证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号